Professor David Johnson

Academic Title-Professor

Princess Alexandra Hospital Southside Clinical Unit
Faculty of Medicine
david.johnson@uq.edu.au
+61 7 3176 5050

Overview

Professor David Johnson

Department of Nephrology, Division of Medicine, ARTS Building, Princess Alexandra Hospital david.johnson2@health.qld.gov.au

David Johnson is currently Director of the Metro South and Ipswich Nephrology and Transplant Service (MINTS) and Medical Director of the Queensland Renal Transplant Service at Princess Alexandra Hospital, Brisbane, Australia, Professor of Medicine and Professor of Population Health at University of Queensland, Director of the Centre for Kidney Disease Research, Theme Leader of Diamantina Health Partners Chronic Disease and Ageing, Chair of the CARI Guidelines Working Parties on Peritoneal Dialysis Adequacy, Evaluation of Renal Function and Management of Early CKD, Chair of the Kidney Check Australia Taskforce, Co-Chair of the Australasian Creatinine and eGFR Consensus Working Party, Co-Chair of the Australasian Proteinuria Consensus Working Party, Founding Member and Deputy Chair of the Australasian Kidney Trials Network (based at Princess Alexandra Hospital), Founding Member of the NHMRC-endorsed Cardiovascular and Renal Centre of Clinical Research Excellence (CCRE), Member of the ANZDATA Registry Peritoneal Dialysis Working Group, International Society of Peritoneal Dialysis Councillor and International Society of Nephrology Councillor. He was Chair of the Queensland Statewide Renal Clinical Network from 2008 until 2013.

He is the principal investigator on a number of large, multi-centre randomised controlled trials, including the balANZ, HERO, IDEAL, IMPENDIA, HONEYPOT and CKD-FIX trials, and is chair of the Data Safety and Monitoring Board for the FINESSE trial. He has published over 630 original manuscripts in peer-reviewed journals and presented over 380 abstracts at national and international scientific meetings. He has won numerous research awards for his clinical and basic science studies in the areas of peritoneal dialysis outcomes, cardiovascular risk factor modification in uraemia, renal transplantation, dialysis unit infection control, treatment of acute renal failure and mechanisms of progressive chronic kidney disease.

In 2005, he was awarded the TJ Neale Award by the Australian and New Zealand Society of Nephrology for “outstanding contributions to nephrologic science.” He was a Queensland finalist in the Australian of the Year Awards for 2009. On Australia Day 2011, he was awarded a Public Service Medal by the Governor-General of Australia for outstanding public service, particularly research into the early detection and management of kidney disease. In 2014, he was awarded an International Distinguished Medal by the US National Kidney Foundation.

Research Interests

  • Peritoneal dialysis
  • Haemodialysis
  • Kidney transplantation
  • Chronic kidney disease

Research Impacts

Chronic kidney disease (CKD) is increasingly recognised as a major public health problem in Australia and worldwide. The prevalence of CKD in Australian adults is between 11.5% and 13.4% (equivalent to 1.4-1.6 million individuals) and is 6 times more common in indigenous Australians than in Caucasians. CKD is the most common cause of hospitalisation in Australia. Each year, approximately 2,500 Australians progress to end-stage kidney disease (ESKD) requiring either dialysis or kidney transplantation. It is projected that by 2020, between 3,335 and 4,472 Australians per year will reach ESKD. The presence of CKD is one of the most potent known risk factors for cardiovascular disease (CVD), such that individuals with CKD are more likely to die, mostly from CVD, than survive to the point of needing dialysis. Kidney-related disease directly or indirectly contributes to the deaths of 13.5% of Australians (more than deaths due to breast cancer, bowel cancer, prostate cancer, suicide and motor vehicle accidents combined). It is one of the few diseases in which mortality rates are worsening over time.

The Centre for Kidney Disease Research (CKDR) is one of Australia’s leading kidney disease research centres with an international reputation for excellence in research. Consisting of the Translational Research Laboratories, Princess Alexandra Hospital Nephrology Clinical Research Group, the Australasian Kidney Trials Network (AKTN) and the Research Unit at Royal Brisbane and Women’s Hospital, the researchers of the CKDR are working at the forefront of global trends in research to understand the cellular and molecular basis of kidney disease and to trial innovative new clinical treatments to improve the health and well-being of people with kidney disease. Renowned for its studies in acute and chronic kidney disease and kidney cancers, the CKDR has particular expertise in translating results from laboratory and clinical sciences for application to improve public health outcomes. Some of the major achivements of our group have been determining the ideal time to commence dialysis, the role of statins in improving cardiovascular outcomes in patients with kidney disease

Qualifications

  • Doctor of Medicine (Research), The University of Queensland
  • PhD, The University of Sydney
  • MBBS, The University of Queensland

Publications

  • Krishnasamy, Rathika, Tan, Sven-Jean, Hawley, Carmel M., Johnson, David W., Stanton, Tony, Lee, Kevin, Mudge, David W., Campbell, Scott, Elder, Grahame J., Toussaint, Nigel D. and Isbel, Nicole M. (2017) Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD. BMC Nephrology, 18 1: . doi:10.1186/s12882-017-0705-4

  • Palmer, Suetonia C., Tunnicliffe, David J., Singh-Grewal, Davinder, Mavridis, Dimitris, Tonelli, Marcello, Johnson, David W., Craig, Jonathan C., Tong, Allison and Strippoli, Giovanni F. M. (2017) Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: A network meta-analysis of randomized trials. American Journal of Kidney Diseases, 70 3: 324-336. doi:10.1053/j.ajkd.2016.12.008

  • Lv, Jicheng, Zhang, Hong, Wong, Muh Geot, Jardine, Meg J., Hladunewich, Michelle, Jha, Vivek, Monaghan, Helen, Zhao, Minghui, Barbour, Sean, Reich, Heather, Cattran, Daniel, Glassock, Richard, Levin, Adeera, Wheeler, David, Woodward, Mark, Billot, Laurent, Chan, Tak Mao, Liu, Zhi-Hong, Johnson, David W., Cass, Alan, Feehally, John, Floege, Juergen, Remuzzi, Giuseppe, Wu, Yangfeng, Agarwal, Rajiv, Wang, Hai-Yan and Perkovic, Vlado (2017) Effect of oral methylprednisolone on clinical outcomes in patients With IgA nephropathy: The TESTING randomized clinical trial. Jama-Journal of the American Medical Association, 318 5: 432-442. doi:10.1001/jama.2017.9362

View all Publications

Grants

View all Grants

Supervision

View all Supervision

Publications

Book

  • National Stroke Foundation, Lalor, Erin, Boyden, Andrew, Cadilhac, Dominique, Colagiur, Stephen, Doust , Jennifer, Fraser, Dianne, Harris , Mark, Huang , Nancy, Johnson, David, Johnson, Greg, Lusis , Nadia, Mathew, Timothy, Muller, Noel, Sharma, Rashmi, Shaw, Jonathan, White , Ian and Wilson, Jinty Guidelines for the management of absolute cardiovascular disease risk. Australia: National Stroke Foundation, 2012.

  • Fahim, Magid A. and Johnson, David W. Hepatitis C infection in dialysis. New York , U.S.A.: Nova Science Publishers Inc, 2010.

  • Chadban, Steve, Harvie, Barb, Johnson, David Wayne, Joyner, Beres, Kidney Check Australia Taskforce, Kidney Health Australia, Ludlow, Marie, Mathew, Tim, Snelling, Paul, Usherwood, Tim, Weekes, Andrew and Wilmot, Sheena Chronic kidney disease (CKD) management in general practice. Melbourne, Vic., Australia: Kidney Health Australia, 2007.

Book Chapter

  • Zirapury, Tasnim, van Eps, Carolyn, Hawley, Carmel M., Badve, Sunil V. and Johnson, David W. (2013). An overview of erythropoietin therapy. In Erythropoietin: human production, potential uses and adverse effects (pp. 31-53) New York, NY, United States: Nova Science Publishers.

  • Badve, Sunil V., Hawley, Carmel M. and Johnson, David W. (2012). How do Clinical Outcomes of Automated Peritoneal Dialysis Compare with those of Continuous Ambulatory Peritoneal Dialysis?. In Stephen Z. Fadem (Ed.), Issues in Dialysis 1st ed. (pp. xx-xx) New York, NY, U.S.A.: Nova Science Publishers.

  • Johnson, David W. (2011). Screening and management: Overview. In John T. Daugirdas (Ed.), Handbook of chronic kidney disease management (pp. 32-43) Philadelphia, PA, U.S.A.: Wolters Kluwer.

  • Fahim, Magid A. and Johnson, David W. (2010). Hepatitis C in dialysis patients. In Leon V. Berhardt (Ed.), Advances in Medicine and Biology (pp. 111-134) New York , U. S. A.: Nova Science Publishers.

  • Johnson, David W. and Williams, John D. (2009). Impact of peritoneal dialysis solutions on outcomes. In Donald Molony and Jonathan Craig (Ed.), Evidence-based nephrology (pp. 500-509) Oxford, United Kingdom: Wiley-Blackwell.

  • Vesey, David A., Qi, Weier, Chen, Xingming, Pollock, Carol A. and Johnson, David W. (2009). Isolation and primary culture of human proximal tubule cells. In John M. Walker, T. D. Hewitson and G. J. Becker (Ed.), Kidney Research: Experimental Protocols (pp. 19-24) Clifton, NJ, U.S.A.: Humana Press. doi:10.1007/978-1-59745-352-3_2

  • Mathew, T. and Johnson, D. W. (2009). Kidney disease. In The Royal Australian College of General Practitioners ‘Red Book’ Taskforce (Ed.), Guidelines for preventive activities in general practice 7th ed. (pp. 46-47) South Melbourne, Vic., Australia: Royal Australian College of General Practitioners.

  • Strippoli, Giovanni F. M., Wiggins, Kathryn J., Johnson, David W., Navaneethan, Sankar, Cancarini, Giovanni and Craig, Jonathan C. (2009). Prevention and treatment of peritoneal dialysis-related infections. In Donald Molony and Jonathan Craig (Ed.), Evidence-based nephrology (pp. 509-535) Oxford, United Kingdom: Wiley-Blackwell.

  • Johnson, David W. and Mathew, Timothy (2008). How to treat proteinuria. In Gavathas (Ed.), How to treat: Australia's leading series on primary care treatment. Yearbook, 2008. (pp. xx-xx) Chatswood, N.S.W., Australia: Reed Business Information.

  • Johnson, David, Excell, Leonie, Livingston, Brian, Bannister, Kym and McDonald, Stephen (2008). Peritoneal Dialysis. In Stephen McDonald, Leonie Excell and Brian Livingston (Ed.), Australia and New Zealand Dialysis and Transplant Registry: The 31st Report 2008 (pp. 6-1-6-20) Adelaide, South Australia: ANZDATA Registry.

  • Johnson, David W. (2007). Hypokalaemia and Metabolic Alkalosis. In D.C.H. Harris (Ed.), Clinical Cases in Kidney Disease (pp. xx-xx) North Ryde, N.S.W.: McGraw-Hill Australia.

  • Johnson, David, Chang, Sean, Excell, Leonie, Livingston, Brian, Bannister, Kym and McDonald, Stephen (2007). Peritoneal dialysis. In Stephen McDonald, Sean Chang and Leonie Excell (Ed.), Australia and New Zealand Dialysis and Transplant Registry: The 30th report 2007 (pp. 6-2-6-18) Adelaide, Australia: ANZDATA Registry.

  • Johnson, David, Chang, Sean, Excell, Leonie, Livingston, Brian, Bannister, Kym and McDonald, Stephen (2006). Peritoneal Dialysis. In Stephen McDonald, Sean Chang and Leonie Excell (Ed.), Australia and New Zealand Dialysis and Transplant Registry: The 29th Report 2006 (pp. 88-102) Adelaide, South Australia: ANZDATA Registry.

  • Johnson, David W. and Mathew, Timothy (2005). Kidney disease. In M. Harris, L. Bailey, C. Bridges-Webb, L. Furler, B. Joyner, J. Litt, J. Smith and Y. Zurynski (Ed.), Guidelines for preventive activities in general practice 6th ed. (pp. xx-xx) Melbourne, Vic.: Royal Australasian College of General Practitioners.

  • Johnson, David, Bannister, Kym, McDonald, Stephen, Excell, Leonie, Livingston, Brian and Shtangey, Victoria (2005). Peritoneal Dialysis. In Stephen McDonald and Leonie Excell (Ed.), Australia and New Zealand Dialysis and Transplant Registry: The 28th Report 2005 (pp. 84-97) Adelaide, South Australia: ANZDATA Registry.

  • Johnson, David (2005). Post-transplant lymphoproliferative disorder. In Australian Cancer Network Diagnosis and Management of Lymphoma Guidelines Working Party (Ed.), Clinical Practice Guidelines for the Diagnosis and Management of Lymphoma (pp. 279-290) Sydney: The Cancer Council Australia/Australian Cancer Network.

  • Wiggins, Kathryn J. and Johnson, David W. (2005). The Influence of Obesity on Outcomes in End-Stage Renal Failure. In Linda A. Ferrara (Ed.), Body Mass Index and Health (pp. 43-57) New York: Nova Science.

  • Excell, Leonie, Johnson, David and McDonald, Stephen (2004). Peritoneal Dialysis. In Leonie Excell and Stephen McDonald (Ed.), Australia and New Zealand Dialysis and Transplant Registry: The 27th Report 2004 (pp. 54-68) Adelaide, South Australia: ANZDATA Registry.

  • Johnson, David (2003). Peritoneal dialysis. In Stephen McDonald and Graeme Russ (Ed.), Australia and New Zealand Dialysis and Transplant Registry: The 26th report 2003 (pp. 46-59) Adelaide, South Australia: ANZDATA Registry.

  • McDonald, Stephen, Johnson, David and Collins, John (2002). The Effect of Body Mass Index on Peritoneal Dialysis Outcome. In Stephen P. McDonald and Graeme R. Russ (Ed.), Australia and New Zealand Dialysis and Transplant Registry: The 25th Report 2002 (pp. 114-117) Adelaide, South Australia.: ANZDATA Registry.

Journal Article

Conference Publication

Other Outputs

Grants (Administered at UQ)

PhD and MPhil Supervision

Current Supervision

Completed Supervision